ClinicalTrials.gg
RecruitingNCT04471064Updated May 18, 2023

A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of XY0206 in Acute Myeloid Leukemia, sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
181st of 433
60 · median 50
Started
2020
with 24 others
Phase 1
121 of 473
69 open now
Primary completion
2024-02
later than 21 of 288 live
Registered
110th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 181st largest by planned enrollment of the 433 interventional ones that give a count, is one of 25 that started in 2020, is one of 121 in phase 1, reaches primary completion later than 21 of the 288 other live ones, and was the 110th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

  1. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML;
  2. Evaluate the dose limited toxicity (DLT) and maximum tolerable dose (MTD) of xy0206 as single drug in the treatment of relapsed / refractory AML subjects.
  3. To evaluate the pharmacokinetic (PK), pharmacokinetic (PD) characteristics and PK / PD correlation of xy0206 as single drug treatment in relapsed / refractory AML subjects;
  4. To evaluate the primary efficacy of xy0206 as single drug in the treatment of relapsed / refractory AML patients;
  5. To evaluate biomarkers of xy0206 as single drug treatment for relapsed / refractory AML subjects.
03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet all of the following criteria before entering the group:

    1. At least 18 years old; 2. Based on the World Health Organization (WHO) 2016 classification, the patients who were confirmed by the morphology of bone marrow cells and met the diagnosis criteria of AML (refer to the Chinese diagnosis and treatment guidelines for relapsed and refractory acute myeloid leukemia (2017 version)), the diagnosis criteria of relapsed AML: after CR, the peripheral blood once again showed leukemia cells or the original / immature cells in bone marrow were more than 5% (except the bone marrow after consolidated chemotherapy) The diagnosis standard of refractory AML: the primary refractory disease that has not been completely relieved after two courses of chemotherapy induced by standard regimen (including cytarabine and an anthracycline or anthraquinone drug); 3. physical fitness score is ≤ 2 points ; 4 Estimated survival time ≥ 12 weeks; 5 The organ function level of subjects must meet the following requirements:
    • Blood routine test: WBC ≤ 30 × 109 / L (it is allowed to take hydroxyurea until 3 days before administration of test drug to stabilize WBC);
    • Blood biochemistry: serum creatinine (Scr) ≤ 1.5 × or rate (Ccr) ≥ 60 ml / min (using Cockcroft -Gault formula); (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 2.5 × ULN (liver with leukemia cell infiltration ≤ 5 × ULN), total (TBIL) ≤ 1.5 × ULN;
    • Electrolyte: the content of potassium, sodium, calcium and magnesium in the blood is within the normal value range of the laboratory (if the abnormal laboratory result judged by the researcher is of no clinical significance or can be controlled within the normal value range by drugs in the screening period, the subject can be included in the group);
    • Coagulation function: ≤ 1.5 × ULN, APTT \< 10 seconds, PT \< 3 seconds, FIB ≥ 1.5g/l (blood products or drugs are allowed to be corrected 3 days before administration of test drugs);
    • Friderica value (QTC) for male ≤ 450 ms or female ≤ 470 MS;
    • ≥ 50%;
    • Urinary protein \< 2 + was detected in urine routine. If urinary protein ≥ 2 +, 24-hour urinary protein quantification is needed, and only when 24-hour urinary protein \< 2g can be enrolled in the group; 6. The serum pregnancy test must be carried out within 28 days before receiving the first dose of study drug and the result must be negative. The women of childbearing age and the male subjects agree to adopt the routine and effective measures during the whole study period and within 6 months after the treatment; 7. The subjects should be willing to provide effective diagnosis evidence before treatment or accept bone marrow puncture or for diagnosis, and accept bone marrow puncture or biopsy for efficacy evaluation after treatment; 8. Volunteer to participate in clinical research and sign in writing.

Exclusion criteria

Exclusion Criteria:

  • Patients cannot participate in this clinical study if they meet any of the following conditions:

    1. Known allergy to the study drug or any of its ingredients; has been treated with sunitinib malate, or allergy to sunitinib malate;
    2. BCR / ABL positive leukemia (chronic myeloid leukemia);
    3. The subjects had central nervous system leukemia;
    4. The subjects had secondary AML after chemotherapy for other tumors (except MDS);
    5. At the same time, patients with other malignant tumors (except for those with cured stage IB or lower grade cervical cancer, non-invasive basal cell or squamous cell skin cancer, malignant melanoma with complete remission (CR) > 10 years, and other malignant tumors with complete remission (CR) > 5 years);
    6. Treatment before the trial:

      • Previous treatment with FLT3 inhibitor;
      • Patients who have received hematopoietic stem cell transplantation before;
      • Received chemotherapy, biotherapy, targeted antitumor therapy within 28 days before starting to use the study drug, and radiotherapy within 14 days;
      • Drugs with significant effect on P450 metabolic enzyme pathway taken within 2 weeks before the screening period;
      • Have participated in other clinical studies and applied research drugs within 28 days before starting to use research drugs;
      • Major surgery or significant traumatic injury within 28 days prior to the first administration of the study treatment or maybe major surgery is needed during the study treatment period;
      • Concomitant drugs that may cause prolongation or induce torsade de pointes (TdP) are required, in addition to antimicrobials used as standard therapy for the prevention or treatment of infection and other such drugs considered essential by the researchers;
    7. The toxic and side effects caused by previous treatment did not recover to ≤ 1, except for hair loss and other tolerable events judged by the researchers;
    8. Combined diseases:

      • One or more , , anti or anti Treponema pallidum specific antibodies are positive;
      • gastrointestinal abnormalities that may affect drug intake, transport or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, peptic ulcer, etc.), subjects with total gastrectomy, or patients with malabsorption syndrome;
      • Have a history of uncontrolled epilepsy, central nervous system disease or mental illness;
      • Hypertension with poor drug control (persistent systolic blood pressure ≥ 150 mmHg and / or diastolic blood pressure ≥ 100 mmHg despite antihypertensive treatment);
      • Poorly controlled diabetes mellitus (fasting blood glucose continues to be > 7.1mmol/L despite hypoglycemic treatment), or insulin-dependent diabetes mellitus (type I diabetes), or non insulin-dependent diabetes mellitus with small vessel disease, or pancreatic dysfunction;
      • In the 12 months before the first application, there were any of the following conditions: symptomatic congestive heart failure ( class II-IV), uncontrolled arrhythmia, angina pectoris, myocardial infarction, stroke (except lacunar infarction), coronary / peripheral artery bypass surgery, pulmonary embolism;
      • Long QT syndrome with congenital long QT interval syndrome or known family history;
      • There is a history of falling below 40%;
      • Uncontrolled active infections (bacteria, viruses, fungi, etc.);
      • Bleeding grade ≥ grade 3 ;
      • Have adrenal insufficiency;
      • The thyroid function was abnormal in the past, or could not be maintained in the normal range even under the condition of drug treatment;
      • Currently, there are serious unhealed wounds, ulcers or fractures;
      • Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN);
    9. For female subjects: currently in pregnancy or lactation;
    10. Any previous or current disease, treatment, or laboratory abnormality that may interfere with the results of the study, affect the subject's participation in the whole process of the study, or the subject is not suitable for the study in the opinion of the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    XY0206-12.5mg

    Drug:XY0206;Dosage form:Tablet;Dosage:12.5mg; multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-25mg

    Drug:XY0206;Dosage form:Tablet;Dosage:25mg; multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-50mg

    Drug:XY0206;Dosage form:Tablet;Dosage:50mg; multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-100mg

    Drug:XY0206;Dosage form:Tablet;Dosage:100mg; multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-150mg

    Drug:XY0206;Dosage form:Tablet;Dosage:150mg; multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-200mg

    Drug:XY0206;Dosage form:Tablet;Dosage:200mg; multiple dose phase

    Drug: XY0206

  • Experimental
    XY0206-250mg

    Drug:XY0206;Dosage form:Tablet;Dosage:250mg; multiple dose phase

    Drug: XY0206

Interventions

  • DrugXY0206

    Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.

06

What researchers measure

Primary outcomes

  1. Maximum tolerable dose

    The occurrence of Maximum tolerable dose.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  2. Dose limiting toxicity

    The occurrence of Dose limiting toxicity.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  3. Adverse event

    The occurrence rate of Adverse event.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  4. Adverse drug reactions

    The occurrence rate of adverse drug reactions.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  5. Serious adverse events

    The occurrence rate of Serious adverse events.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  6. Blood routine

    Check whether the red blood cell system, white blood cell system and platelet system are normal

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  7. Urine routine

    Urine routine examination includes urine color, transparency, pH, red blood cells, white blood cells, epithelial cells, tube type, protein, specific gravity and urine sugar.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  8. Stool routine

    Routine stool tests include the detection of red and white blood cells in feces, bacterial sensitivity test, occult blood test (OB) and inspection of eggs.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  9. Blood biochemistry

    The contents of various ions, sugars, lipids, proteins, enzymes, hormones and metabolites in blood were detected

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  10. Serum amylase / lipase

    Evaluation of pancreatic function

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  11. Coagulation function

    Four coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB) were evaluated.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  12. ECG

    Evaluation of QT interval

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  13. Echocardiography

    To evaluate the electrophysiological condition of the heart

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  14. Imaging examination

    Chest X-ray/CT

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  15. Body temperature

    One of the vital signs.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  16. Blood pressure

    Assess whether systolic blood pressure and diastolic blood pressure are normal

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  17. Heart rate

    One of the vital signs.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  18. Breathing

    Assess if breathing is normal

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  19. Skin

    Assess if the skin is normal.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  20. Head

    Head examination includes head, eyes, ears, nose, lips, etc.Assess if head is normal

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  21. Neck

    Neck examination includes thyroid gland, lymph node, etc.Assess if neck is normal.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  22. Chest

    Chest examination includes lung, cardiovascular, etc.Assess if chest is normal.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  23. Abdomen

    Abdominal examination includes liver and spleen.Assess if abdomen is normal.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  24. Limbs

    Assess if limbs is normal.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  25. Nerves

    Assess nerve function by communication

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

  26. Back/spine

    Assess if back/spine is normal.

    Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Feb 2024, 41 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 41 months is close to that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2020
First posted
Jul 14, 2020
StartActual
Sep 15, 2020
Primary completionEst.
Feb 2024
CompletionEst.
Feb 2024
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04471064
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Collaborators
Proswell Medical Corporation
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Sep 15, 2020
Primary completion
Feb 2024 (estimated)
Completion
Feb 2024 (estimated)
Last update
May 18, 2023

Study contacts

wei Wang, master
Contact
wangwei001@yiling.cn
086-0311-66703017
Jianxiang Wang, MD
Contact
wangjx@ihcams.ac.cn
022-23909120
Junyuan Qi, MD
principal investigator · Institute of Hematology, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FLT3 Inhibitor XY0206

Start the discussion